Now showing 1 - 10 of 10
  • 2005Journal Article
    [["dc.bibliographiccitation.firstpage","267"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Zeitschrift für Gastroenterologie"],["dc.bibliographiccitation.lastpage","273"],["dc.bibliographiccitation.volume","43"],["dc.contributor.author","Schindler, C. G."],["dc.contributor.author","Armbrust, T."],["dc.contributor.author","Gunawan, Bastian"],["dc.contributor.author","Langer, C."],["dc.contributor.author","Fuzesi, Laszlo"],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2018-11-07T11:22:29Z"],["dc.date.available","2018-11-07T11:22:29Z"],["dc.date.issued","2005"],["dc.description.abstract","Background: The tyrosine kinase inhibitor imatinib has been introduced into the treatment of gastrointestinal stromal tumors (GIST). Here we report our results of prolonged treatment in comparison to a similar group of GIST patients who had died before imatinib became available. Methods: Fourteen patients with recurrent or metastatic GIST were treated with imatinib. Clinical data and tumor samples of ten patients from the pre-imatinib era were available for comparison. Comparative genomic hybridisation (CGH) was performed on tumors to identify changes that may predict response to treatment. Results: Fourteen patients were treated, mean treatment time 22.3 months (1 nonresponse, 2 progression after initial response, 2 stable diseases, 8 partial responses, 1 complete response). Adverse side effects were mild in general. Survival was higher in the treated group (41.1 months vs. 34.8 months in the historical group). Eleven treated patients are alive. CGH analysis showed comparable numbers of chromosomal aberations in both groups. Conclusion: Prolonged treatment with imatinib is safe and effective in patients with recurrent or metastatic GIST."],["dc.identifier.doi","10.1055/s-2004-813756"],["dc.identifier.isi","000228096400003"],["dc.identifier.pmid","15765299"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56004"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","1439-7803"],["dc.relation.issn","0044-2771"],["dc.title","Gastrointestinal Stromal Tumor (GIST) - Single center experience of prolonged treatment with imatinib"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC WOS
  • 1998Journal Article
    [["dc.bibliographiccitation.firstpage","443"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Hepatology"],["dc.bibliographiccitation.lastpage","449"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Nolte, Wilhelm"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Schindler, Christian G."],["dc.contributor.author","Unterberg, Knut"],["dc.contributor.author","Finkenstaedt, Michael"],["dc.contributor.author","Niedmann, Peter D."],["dc.contributor.author","Hartmann, Heinz"],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2017-09-07T11:44:25Z"],["dc.date.available","2017-09-07T11:44:25Z"],["dc.date.issued","1998"],["dc.description.abstract","Background/Aims: Deposition of paramagnetic substances in basal ganglia, resulting in increased signals in T1-weighted magnetic resonance images (bright basal ganglia), is frequently seen in liver cirhrosis. The present study describes the prevalence of bright basal ganglia and its clinical significance in patients with long-standing portal vein thrombosis in the absence of liver cirrhosis.Methods: Six patients with angiographically proven complete portal vein thrombosis and cavernomatous transformation without signs of acute or chronic liver disease were studied by magnetic resonance imaging of the brain, neuropsychiatric evaluation, psychometric tests, electroencephalography, and determination of arterial ammonia levels and of serum manganese concentrations from peripheral venous blood.Results: Five out of six patients demonstrated increased signal intensity in the basal ganglia. Overt portal-systemic encephalopathy was not noted prior to or at the time of evaluation. Normal EEG results were recorded in all patients. Only one of the six patients had pathological results in at least two out of four psychometric tests. This latter patient had had a large right-sided brain infarction. Arterial ammonia concentrations were normal in four of the six patients; one patient with increased ammonia levels had concomitant renal insufficiency with azotemia. The other four patients had no relevant concomitant diseases. Serum manganese levels were non-significantly increased compared with control group (p=0.06), but they were significantly correlated to basal ganglia signal intensity (R=0.88; p=0.02).Conclusions: Our results demonstrate that bright basal ganglia primarily represent shunt-induced alterations. They are not directly associated with disturbed liver function nor with portal-systemic encephalopathy."],["dc.identifier.doi","10.1016/s0168-8278(98)80063-9"],["dc.identifier.gro","3151659"],["dc.identifier.pmid","9764992"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8476"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","chake"],["dc.relation.issn","0168-8278"],["dc.title","Bright basal ganglia in T1-weighted magnetic resonance images are frequent in patients with portal vein thrombosis without liver cirrhosis and not suggestive of hepatic encephalopathy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC
  • 2004Journal Article
    [["dc.bibliographiccitation.firstpage","389"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","European Journal of Gastroenterology & Hepatology"],["dc.bibliographiccitation.lastpage","395"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Wietzke-Braun, Perdita"],["dc.contributor.author","Schindler, C."],["dc.contributor.author","Raddatz, Dirk"],["dc.contributor.author","Braun, F."],["dc.contributor.author","Armbrust, T."],["dc.contributor.author","Nolte, W."],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2018-11-07T10:49:51Z"],["dc.date.available","2018-11-07T10:49:51Z"],["dc.date.issued","2004"],["dc.description.abstract","Objective Patients with non-resectable liver metastases of colorectal cancer have poor prognosis and are mainly treated by palliative chemotherapy. Laser interstitial thereto-therapy is an innovative minimal invasive procedure for local tumour destruction within solid organs. The aim of the study was to investigate quality of life and outcome of ultrasound-guided laser interstitial thermotherapy (US-LITT) in patients with liver metastases of colorectal cancer. Methods In this prospective non-randomized study, 45 patients with liver metastases of colorectal cancer were palliatively treated by US-LITT. Patient survival was analysed by the Kaplan-Meier method and the quality of life by questionnaire C30 of the European Organisation for Research and Treatment of Cancer before, and 1 week, 1 month, and 6 months after initiation of US-LITT. Results Median survival after initiation of US-LITT was 8.5 +/- 0.7 months with a range of 1.5-18 months. Body weight was constant 1 month after US-LITT. In the multivariate analyses, quality-of-life symptoms and functioning scales did not deteriorate in patients alive at 6 months after initiation of US-LITT. Univariate analyses outlined a significant increase of the pain subscale before and at 1 week after US-LITT. Conclusions This study first describes the quality of life in patients with liver metastases of colorectal cancer treated by US-LITT. Potential benefits of the minimal invasive procedure could be prolonged survival time by preserved quality of life, but this first impression needs to be verified in a comparative study."],["dc.identifier.doi","10.1097/00042737-200404000-00004"],["dc.identifier.isi","000220655900004"],["dc.identifier.pmid","15028971"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48527"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0954-691X"],["dc.title","Quality of life and outcome of ultrasound-guided laser interstitial thereto-therapy for non-resectable liver metastases of colorectal cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC WOS
  • 2001Journal Article
    [["dc.bibliographiccitation.firstpage","580"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","The Journal of Pathology"],["dc.bibliographiccitation.lastpage","585"],["dc.bibliographiccitation.volume","195"],["dc.contributor.author","Reuther, F. J."],["dc.contributor.author","Löhler, J."],["dc.contributor.author","Herms, J."],["dc.contributor.author","Hugo, H. H."],["dc.contributor.author","Schindler, C."],["dc.contributor.author","Leithäuser, F."],["dc.contributor.author","Melzner, I."],["dc.contributor.author","Möller, P."],["dc.contributor.author","Scheil, S."],["dc.date.accessioned","2018-11-07T11:21:43Z"],["dc.date.available","2018-11-07T11:21:43Z"],["dc.date.issued","2001"],["dc.description.abstract","Between 1955 and 1963, millions of children and adults were exposed to SV40-contaminated poliovirus vaccines. The oncogenic potential of this polyomavirus was revealed when intracerebral inoculation of SV40 into newborn hamsters resulted in the development of ependymomas and choroid plexus papillomas. Subsequently, SV40-like sequences were repeatedly detected in human ependymomas with broadly ranging incidence rates of 7-90%. Most epidemiological studies, however, have not described an increased occurrence of ependymomas. To gain more data on this controversial issue, this study examined 62 archived ependymal tumours from 31 children and 31 adults who underwent surgery between 1990 and 1999. Only three (5%) of the tumours - including 24 classical, 20 anaplastic, and 12 myxopapillary ependymomas; one subependymoma; and five ependymoblastomas - revealed subgenomic SV40 sequences. None of the ependymomas in patients born between 1920 and 1960 demonstrated SV40-like sequences. The positive tumours represent 7% of grade II and III ependymomas (two paediatric and one adult tumour). DNA sequencing of the PCR product revealed identical sequences of SV40 in the positive ependymal tumours. Compared with the results from other countries, this incidence rate is relatively low. Therefore, it seems likely that significant differences between individual countries exist regarding the prevalence of SV40-positive ependymomas. These differences may reflect different degrees of exposure to SV40-contaminated polio vaccine. Copyright (C) 2001 John Wiley & Sons, Ltd."],["dc.identifier.doi","10.1002/path.1005"],["dc.identifier.isi","000172595500009"],["dc.identifier.pmid","11745694"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55842"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","John Wiley & Sons Ltd"],["dc.relation.issn","0022-3417"],["dc.title","Low incidence of SV40-like sequences in ependymal tumours"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC WOS
  • 2000Journal Article
    [["dc.bibliographiccitation.firstpage","60"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Liver International"],["dc.bibliographiccitation.lastpage","65"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Nolte, Wilhelm"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Pahl, Karoline"],["dc.contributor.author","Unterberg, Knut"],["dc.contributor.author","Kamrowski-Kruck, Heike"],["dc.contributor.author","Schindler, Christian G."],["dc.contributor.author","Figulla, Hans Reiner"],["dc.contributor.author","Buchwald, Arnd B."],["dc.contributor.author","Hartmann, Heinz"],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2017-09-07T11:44:24Z"],["dc.date.available","2017-09-07T11:44:24Z"],["dc.date.issued","2000"],["dc.description.abstract","Aims/Background: Endothelin-1 (ET-1) may be a mediator for portal hypertension in liver cirrhosis. The aim of the present study was to determine the concentrations of ET-1 in the systemic and splanchnic circulation before and after reduction of portal hypertension by transjugular intrahepatic portosystemic shunt implantation (TIPS). Methods: Plasma concentrations of immunoreactive ET-1 were measured in peripheral venous blood samples from 25 patients with liver cirrhosis before and at 1, 3, 9 and 15 months after TIPS. Furthermore, acute effects of TIPS on ET-1 were studied in plasma samples from the hepatic vein, the portal vein 30 minutes before and after TIPS and in the femoral artery (only after TIPS) in a subgroup of 15 patients. In addition, the portocaval pressure gradient was determined before and after TIPS. Results: Before TIPS peripheral venous plasma ET-1 concentrations (n=25; median 4.2 pg/ml; range 1.9–14.7) were significantly increased in patients with refractory ascites (n=7; median 7.8, range 3.5–14.7) compared to patients with repetitive bleeding (n=18; median 3.4; range 1.9–7.1) (p=0.003). Furthermore, peripheral ET-1 concentrations correlated with the degree of liver dysfunction according to the Child-Pugh classification (Spearman's r=0.46; p=0.02). Following TIPS, peripheral ET-1 concentrations remained unchanged during a follow-up of 15 months. Before TIPS, a positive gradient of ET-1 concentrations from portalvenous to hepatovenous and peripheral venous levels was found (p<0.03). Immediately after TIPS, arterial ET-1 concentrations reached markedly increased levels in individual patients (88, 92 and 103 pg/ml). Severe systemic reactions to these high levels were not observed. Peripheral venous, hepatovenous and portalvenous ET-1 concentrations did not correlate with portocaval pressure gradients. Conclusion: Cirrhotic patients demonstrated unchanged peripheral venous ET-1 concentrations up to 15 months after TIPS. Portal congestion was associated with increased ET-1 levels in the prehepatic splanchnic area. The effect of portal decompression on splanchnic and systemic ET-1 levels deserves further investigation."],["dc.identifier.doi","10.1034/j.1600-0676.2000.020001060.x"],["dc.identifier.gro","3151647"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8464"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","chake"],["dc.relation.issn","1478-3223"],["dc.title","Systemic and splanchnic endothelin-1 plasma levels in liver cirrhosis before and after transjugular intrahepatic portosystemic shunt (TIPS)"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]
    Details DOI
  • 2001Conference Abstract
    [["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Acta Neuropathologica"],["dc.bibliographiccitation.volume","102"],["dc.contributor.author","Scheil, S."],["dc.contributor.author","Reuther, F. J."],["dc.contributor.author","Löhler, J."],["dc.contributor.author","Herms, J."],["dc.contributor.author","Hugo, H. H."],["dc.contributor.author","Schindler, C."],["dc.contributor.author","Leithäuser, F."],["dc.contributor.author","Melzner, I."],["dc.contributor.author","Möller, P."],["dc.date.accessioned","2018-11-07T11:24:49Z"],["dc.date.available","2018-11-07T11:24:49Z"],["dc.date.issued","2001"],["dc.format.extent","539"],["dc.identifier.isi","000171662200111"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56489"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.issn","0001-6322"],["dc.title","Low incidence of SV40-like sequences in ependymal tumours"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]
    Details WOS
  • 2000Journal Article Discussion
    [["dc.bibliographiccitation.firstpage","111"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","LEBER MAGEN DARM"],["dc.bibliographiccitation.lastpage","113"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Schindler, C."],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2018-11-07T10:55:10Z"],["dc.date.available","2018-11-07T10:55:10Z"],["dc.date.issued","2000"],["dc.identifier.isi","000086909400001"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49723"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pflaum Verlag Kg"],["dc.relation.issn","0300-8622"],["dc.title","Intravenous albumin substitution for the treatment of hepatogenous ascites: Rediscovery of an ancient therapeutical concept"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]
    Details WOS
  • 2001Journal Article
    [["dc.bibliographiccitation.firstpage","818"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal of Hepatology"],["dc.bibliographiccitation.lastpage","824"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Nolte, W."],["dc.contributor.author","Schindler, C. G."],["dc.contributor.author","Figulla, H. R."],["dc.contributor.author","Wuttke, Wolfgang"],["dc.contributor.author","Hufner, M."],["dc.contributor.author","Hartmann, Hans"],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2018-11-07T09:00:58Z"],["dc.date.available","2018-11-07T09:00:58Z"],["dc.date.issued","2001"],["dc.description.abstract","Background/Aims: Liver cirrhosis is frequently associated with sexual dysfunction and hormonal abnormalities, To evaluate the effect of portosystemic shunting on sex steroid serum concentrations, a prospective study was performed in cirrhotic patients treated consecutively and electively by transjugular intrahepatic portosystemic stent shunt (TIPS). Methods: In 27 patients with liver cirrhosis we measured serum levels of testosterone (T), sexual hormone binding globulin (SHBG), luteinizing hormone, follicle-stimulating hormone, dehydroepiandrosterone sulfate, androstenedione (A), estradiol (E-2), 17-OH-progesterone and the T/SHBG ratio before and 3 months after TIPS, Results: In men (n = 17) 3 months after TIPS, A and E-2 significantly increased, with mean serum levels rising from 4.4 +/- 2.5 to 5.6 +/- 2.9 ng/ml (P = 0.04) and from 27 +/- 9 to 40 +/- 19 pg/ml (P = 0.003), respectively. In contrast to A the increase of E-2 persisted at 9 and 15 months after TIPS, Erectile dysfunction increased from 30% before TIPS to 70% after TIPS, In women (n = 10) A and E-2 levels did not change significantly after TIPS. Conclusions: TIPS aggravated hormonal dysbalance of ses steroids in favor of estrogens (hyperestrogenism) in men, (C) 2001 European Association for the Study of the Liver. Published by Elsevier Science B.V. All rights reserved."],["dc.identifier.doi","10.1016/S0168-8278(01)00052-6"],["dc.identifier.isi","000169542500005"],["dc.identifier.pmid","11451164"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24297"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1600-0641"],["dc.relation.issn","0168-8278"],["dc.title","Increase of serum estradiol in cirrhotic men treated by transjugular intrahepatic portosystemic stent shunt"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC WOS
  • 2004Journal Article
    [["dc.bibliographiccitation.firstpage","421"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","The Journal of Pathology"],["dc.bibliographiccitation.lastpage","429"],["dc.bibliographiccitation.volume","202"],["dc.contributor.author","Gunawan, Bastian"],["dc.contributor.author","Schulten, Hans-Juergen"],["dc.contributor.author","von Heydebreck, Anja"],["dc.contributor.author","Schmidt, B."],["dc.contributor.author","Enders, C."],["dc.contributor.author","Hoer, J."],["dc.contributor.author","Langer, C."],["dc.contributor.author","Schuler, P."],["dc.contributor.author","Schindler, C. G."],["dc.contributor.author","Kuhlgatz, J."],["dc.contributor.author","Fuzesi, Laszlo"],["dc.date.accessioned","2018-11-07T10:50:00Z"],["dc.date.available","2018-11-07T10:50:00Z"],["dc.date.issued","2004"],["dc.description.abstract","Although the significance of tumour site for estimating malignant potential in gastrointestinal stromal tumours (GISTs) has recently been recognized, site-specific genetic patterns have not to date been defined. This study examined 52 e-kit-positive primary GISTs (with a mean follow-up of 42.3 months in 51 cases) from three different locations (35 gastric, 12 small intestinal, and five colorectal) using comparative genomic hybridization (CGH). In general, tumour site correlated with key prognostic factors, including tumour size, mitotic rate, proliferative activity, and probable malignant potential. Furthermore, several DNA copy number changes showed a site-dependent pattern. These included losses at 14q (gastric 83%, intestinal 35%; p = 0.001), losses at 22q (gastric 46%, intestinal 82%; p = 0.02), losses at 1p (gastric 23%, intestinal 88%; p = 1 x 10(-5)), losses at 15q (gastric 14%, intestinal 59%; p = 0.002), losses at 9q (gastric 14%, intestinal 53%; p = 0.006), and gains at 5p (gastric 11%, intestinal 53%; p = 0.002). These data demonstrate strong site-dependent genetic heterogeneity in GISTs that may form a basis for subclassification. Prognostic evaluation of DNA copy number changes identified losses at 9q as a site-independent prognostic marker associated with shorter disease-free survival (p = 0.03) and overall survival (p = 0.002). Furthermore, 9q loss also appeared to carry prognostic value in predicting overall survival for patients with advanced or progressive GISTs (p = 0.003). Copyright (C) 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley Sons, Ltd."],["dc.identifier.doi","10.1002/path.1537"],["dc.identifier.isi","000220515000005"],["dc.identifier.pmid","15095269"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48560"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","John Wiley & Sons Ltd"],["dc.relation.issn","0022-3417"],["dc.title","Site-independent prognostic value of chromosome 9q loss in primary gastrointestinal stromal tumours"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC WOS
  • 1998Journal Article
    [["dc.bibliographiccitation.firstpage","1215"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Hepatology"],["dc.bibliographiccitation.lastpage","1225"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Nolte, Wilhelm"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Schindler, Christian"],["dc.contributor.author","Münke, Hans"],["dc.contributor.author","Unterberg, Knut"],["dc.contributor.author","Zumhasch, Uta"],["dc.contributor.author","Figulla, Hans R."],["dc.contributor.author","Werner, Gerald"],["dc.contributor.author","Hartmann, Heinz"],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2017-09-07T11:44:23Z"],["dc.date.available","2017-09-07T11:44:23Z"],["dc.date.issued","1998"],["dc.description.abstract","A prospective study of hepatic encephalopathy (HE) including neuropsychiatric and psychometric evaluation, electroencephalography, and determination of arterial ammonia levels was performed in 55 cirrhotic patients treated consecutively by transjugular intrahepatic portosystemic shunt (TIPS). The cumulative HE rate increased from 23.6% within the 3-month interval before TIPS to 50.9% within the first 3-month interval post-TIPS (P = .003). Significant and independent predictors of HE post-TIPS were the presence of HE pre-TIPS and reduced liver function. The cumulative HE rate declined in the second 3-month interval post-TIPS and reached the pre-TIPS level. Chronic forms of HE exceeding grade I were not observed. In a subgroup of 22 nonencephalopathic TIPS patients, the prevalence of subclinical HE did not change after TIPS. Among individual psychometric tests, the block design test gave the highest proportion of pathological results (about 50%), whereas selective reminding gave the lowest (10%-25%). Electroencephalography (EEG) showed a temporary increase of pathological results at 1 month after TIPS, when patients with overt HE (grade I) were included (proportion of 21.1% before vs. 57.1%, P = .005). Arterial ammonia concentration increased from a mean of 94 ± 26 μg/dL to 140 ± 28 μg/dL at 3 months after TIPS (P < .001). Elevated ammonia levels persisted. TIPS led to a temporary increase of HE incidence within 3 months. The decline of the HE rate beyond 3 months despite a sustained increase of arterial ammonia levels could not entirely be explained by reduction of shunt flow, nor by alteration of liver function. Instead, cerebral adaptation to gut-derived neurotoxins might be anticipated."],["dc.identifier.doi","10.1002/hep.510280508"],["dc.identifier.gro","3151638"],["dc.identifier.pmid","9794904"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8454"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","chake"],["dc.relation.issn","0270-9139"],["dc.title","Portosystemic Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt in Patients With Cirrhosis: Clinical, Laboratory, Psychometric, and Electroencephalographic Investigations"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC